PhaseBio Pharmaceuticals Free Cash Flow Margin

Free Cash Flow Margin of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2020 was -19177.81% (a 171.91% increase from previous year)
  • Annual Free Cash Flow Margin for 2019 was -7052.87% (a 174.36% increase from previous year)
  • Annual Free Cash Flow Margin for 2018 was -2570.66% (a -Infinity% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending June 29, 2021 was -420.82% (a -Infinity% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin decreased by -Infinity% year-over-year
Trailing Free Cash Flow Margin for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-420.82% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of PhaseBio Pharmaceuticals

Most recent Free Cash Flow Marginof PHAS including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -19177.81%
2019 -7052.87%
2018 -2570.66%
2017 0.0%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.